Jan 1, 1976

Pharmacotherapy of myocardial ischemia

Major Problems in Internal Medicine
R Gorlin


The cornerstones of pharmacotherapy for myocardial ischemia are the nitrites and the beta-adrenergic blocking agents. These drugs not only inhibit cardiac mechanical activity (and therefore energy requirements) in a variety of ways but also redistribute available blood flow to the potentially ischemic segments of cardiac muscle. The least effective dose of nitroglycerin and the most tolerated (or blocking) dose of propranolol provide the optimum in management. There is increasing evidence that certain orally administered nitrates at larger than usual dosage can further increase the tolerance to effort. Amelioration of hypertension or congestive failure may play a significant role in selected patients.

  • References
  • Citations


  • We're still populating references for this paper, please check back later.
  • References
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Coronary Circulation
Diastolic Blood Pressure
Myocardial Ischemia
Cardiac Glycosides
Blood Flow
Coronary Arteriosclerosis
Pulmonary Vascular Resistance
Diuretic Effect
Sinus Node Artery

About this Paper

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.